Advertisement

Medical Toxicology

, Volume 1, Issue 4, pp 300–307 | Cite as

Acute Overdose with Sustained Release Drug Formulations

Perspectives in Treatment
  • Anil Minocha
  • Daniel A. Spyker
Concepts in Toxicology Review

Summary

Acute overdose with sustained release formulations presents special problems for the health care system. Proper management requires a basic understanding of the pharmacokinetic and pharmacodynamic characteristics of the drugs taken in overdose because different techniques employed by the manufacturers to produce sustained release formulations lead to differences in these characteristics in comparison with conventional formulations. In general, with sustained-release formulations, there is a prolongation of the time for the patient to manifest toxicity (‘preclinical phase’), as well as the period of high drug concentrations and clinical toxicity (‘toxic phase’) and the resolution phase (clinical improvement with declining drug concentrations).

Continued drug absorption over a prolonged period alters the normal drug concentration-time profile. The prolonged absorption half-life may appear as an increase in elimination half-life, even though the clearance of the drug stays the same.

Gastrointestinal decontamination is extremely important in the management of overdose with sustained release formulations. We advocate an aggressive decontamination approach to management, especially in the preclinical phase. With a history of potentially toxic ingestion of an adsorbable drug, a charcoal stool following administration of oral activated charcoal should be a minimum requirement for discharge of the patient. Gastrointestinal decontamination is critical in the preclinical and the toxic phases and may be of value during the resolution phase until the drug concentrations decline to the therapeutic range.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Achong MR, Fernandez FG, McLeod PJ. Fatal self poisoning with lithium carbonate. Canadian Medical Association Journal 112: 868–870, 1975PubMedGoogle Scholar
  2. Amdisen A, Sjogren J. Lithium absorption from sustained release tablets. Acta Pharmacologica Suecica 5: 465–472, 1968Google Scholar
  3. Berlinger WG, Spector R, Goldberg MJ. Enhancement of theophylline clearance by oral activated charcoal. Clinical Pharmacology and Therapeutics 33: 351–354, 1983PubMedCrossRefGoogle Scholar
  4. Buckley BM, Braithwaite RA, Vale JA. Theophylline poisoning. Lancet 2: 618, 1983PubMedCrossRefGoogle Scholar
  5. Connell JMC, McGeachie JF, Knepil J, Thompson A, Junor B. Self poisoning with sustained release aminophylline: secondary rise in serum theophylline concentration after charcoal haemoperfusion. British Medical Journal 284: 943, 1982PubMedCrossRefGoogle Scholar
  6. Conrad KA. Innovations in drug delivery. Postgraduate Medicine 76: 71–79, 1984PubMedGoogle Scholar
  7. Cupit GC, Temple AR. Gastrointestinal decontamination in the management of the poisoned patient. Emergency Medical Clinics of North America 2: 15–28, 1984Google Scholar
  8. Dederich RA, Szefler SJ, Green ER. Intrasubject variation in sustained release theophylline absorption. Journal of Allergy and Clinical Immunology 67: 465–471, 1981PubMedCrossRefGoogle Scholar
  9. Ehrlich BE, Diamond JM. Lithium absorption: implications for sustained release lithium preparations. Lancet 1: 206, 1983Google Scholar
  10. Green JA. Indomethacin sustained release? Drug Intelligence and Clinical Pharmacy 18: 1004–1007, 1984PubMedGoogle Scholar
  11. Hansen HE, Amdisen A. Lithium intoxication. Quarterly Journal of Medicine 186: 123–144, 1978Google Scholar
  12. Helliwell M, Berry D. Theophylline poisoning in adults. British Medical Journal 2: 1114, 1979PubMedCrossRefGoogle Scholar
  13. Helliwell M, Berry D. Theophylline absorption by efferevescent activated charcoal. Journal of International Medical Research 9: 222–225, 1981PubMedGoogle Scholar
  14. Hore P, Bones P, Rollinson T, Ikram H. A pharmacokinetic comparison of two sustained release oral procainamide preparations. British Journal of Clinical Pharmacy 8: 267–271, 1979CrossRefGoogle Scholar
  15. Howrei DL, Wolfson JH. Phenylpropanolamine induced seizures. Journal of Pediatrics 102: 143–145, 1983CrossRefGoogle Scholar
  16. Illingworth RN, Proudfoot AT. Rapid poisoning with slow release potassium. British Medical Journal 281: 485–486, 1980PubMedCrossRefGoogle Scholar
  17. Jefferys DB, Raper SM, Helliwell M, Berry DJ, Crome P. Haemoperfusion for theophylline overdose. British Medical Journal 280: 1167, 1980PubMedCrossRefGoogle Scholar
  18. Johnson GFS, Hunt GE. Pharmacokinetics of lithium preparations in patients. Progress in Neuro-psychopharmacology and Biological Psychiatry 8: 63–70, 1984PubMedCrossRefGoogle Scholar
  19. Karim A, Schubert EN, Burns TS. Disopyramide plasma concentrations following single and multiple doses of immediate and controlled release capsules. Angiology 34: 375–392, 1983PubMedCrossRefGoogle Scholar
  20. Krenzelok EP, Keller R, Stewart RD. Elimination of activated charcoal with cathartics. Annals of Emergency Medicine 14: 1152–1155, 1985PubMedCrossRefGoogle Scholar
  21. Marini JL, Sheard MH. Sustained-release lithium carbonate in a double blind study: serum lithium levels, side effects and placebo response. Journal of Clinical Pharmacology 16: 276–283, 1976PubMedGoogle Scholar
  22. Minocha A, Herold DA, Bruns DE, Spyker DA. Effect of activated charcoal in 70% sorbitol in healthy individuals. Clinical Toxicology 22: 529–536, 1985CrossRefGoogle Scholar
  23. Park GD, Spector R, Goldberg MJ, Johnson GF, Feldman R, et al. Effect of the surface area of activated charcoal on theophylline clearance. Journal of Clinical Pharmacology 24: 289–292, 1984PubMedGoogle Scholar
  24. Rider JA. Potassium chloride preparations and fecal blood loss. Journal of the American Medical Association 231: 836, 1975PubMedCrossRefGoogle Scholar
  25. Spyker DA, Minocha A. Toxicodynamic approach to management of the poisoned patient. Manuscript in preparation, 1986Google Scholar
  26. Steger W. Treatment of hypertensive outpatients with a sustained-release dosage form of clonidine: a comparison with standard tablet therapy and long term follow-up study. Current Medical Research and Opinion 6: 670–675, 1980PubMedCrossRefGoogle Scholar
  27. Tabachnik E, Scott P, Correia J. Sustained release theophylline: a significant advance in the treatment of childhood asthma. Journal of Pediatrics 100: 489–492, 1982PubMedCrossRefGoogle Scholar
  28. Urquhart J. Rate controlled drug dosage. Drugs 23: 207–226, 1982PubMedCrossRefGoogle Scholar
  29. Weinberger M, Hendeles L. Slow release theophylline: rationale and basis for product selection. New England Journal of Medicine 308: 760–764, 1983PubMedCrossRefGoogle Scholar
  30. Weinberger MC. Theophylline. In Rumack BH (Ed.) Poisindex, Micromedex Inc., Denver, 1985Google Scholar

Copyright information

© ADIS Press Limited 1986

Authors and Affiliations

  • Anil Minocha
    • 1
  • Daniel A. Spyker
    • 1
  1. 1.Division of Clinical Pharmacology, Department of Internal MedicineUniversity of Virginia Medical CenterCharlottesvilleUSA

Personalised recommendations